News

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

There were no associations found between infantile colic and the risk of developing functional gastrointestinal disorders at age 4-6.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

Investigators noted that the psychosocial impacts of food allergy have only intensified with the introduction of the COVID-19 virus.

The biologic sustained responses in managing sleep interference with numerically higher responses than omalizumab.

Clinical results show that 98% of patients with relapsed or refractory multiple myeloma responded to cilta-cel after a single treatment.

General progress has been made in decreasing diabetes mortality at ages younger than 25 years, but challenges remain in low and low-middle SDI countries.

It was unknown prior to the study if dupilumab treatment improved skin microbial and barrier abnormalities in patients with atopic dermatitis.

Long-term care facilities were able to see a reduction in antibiotic starts and days of antibiotic therapy by engaging in an antibiotic stewardship program.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

Investigators noted that the study of the atopic march has largely focused on White populations that biased current paradigms

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

The FDA granted accelerated approval to the treatment of adults with intermediate or high-risk primary or second myelofibrosis.

Expert Mikkael Sekeres, MD, explains that the COVID-19 pandemic affected all of medicine, but in a rare disease domain that impact was even greater.

Clinical and industry leaders share their perspectives on the importance of collaboration in developing treatments for rare diseases.

Expert John Sergent, MD, goes into detail about myositis and how to differentiate it from other inflammatory diseases.

The FDA asked the company to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

Those who are underweight or normal weight were more likely to have an IgE mediated food allergy.

These prominent leaders in the field of autoimmune disease discuss AHN's Autoimmunity Institute joining forces with the Relapsing Polychondritis Foundation.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

Chief Scientific Officer of the CMT Research Foundation talks about being cognizant of the blood-nerve barrier when treating patients and developing therapies.

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

The president of Make-A-Wish New Jersey speaks about the impact of granting a wish to a child living with a rare disease.

Gestational age and NICU admission both were associated with the risk of developing EoE.

The Rare Disease Report Podcast returns! Our first episode features Karen Kozarsky, PhD, an expert on gene therapy and adrenomyelonueropathy.

Why is Rare Disease Day so important? Hear the answers from some of the most qualified professionals in rare disease fields.

The reductions were seen as early as week 2 and was sustained throughout the 52 week study.